Luminaries Forum Highlights Early Intervention & the Latest Advancements
in Myopia Management
INDIANAPOLIS, November 12, 2024—CooperVision demonstrated its role as a leader in myopia management at Academy 2024 in Indianapolis last week, which coincided with the fifth anniversary of MiSight® 1 day’s FDA approval.* This milestone was celebrated at the 2024 Myopia Luminaries Forum, where leading eye care professionals (ECPs) gathered to highlight groundbreaking achievements in myopia management, discuss the latest scientific advancements, and reflect on the significant impact MiSight® 1 day has made over the past five years in correcting and helping to protect the vision and eye health of age-appropriate children with myopia across the U.S.*†‡1,2
"Celebrating this five-year milestone with some of the brightest minds in the industry was a meaningful way to honor this journey,” said Justin Kwan, OD, FAAO, Head, Myopia Management, CooperVision. “Being the first to market is never easy, but when it comes to children’s eye health, it’s essential. Taking the time to reflect on the tremendous work of the past five years and building excitement for the future was the perfect way to kick off Academy this year."*¶1
Prominent experts in the field of myopia spoke at the event, which included:
- key scientific updates in the field from Maria Liu, Ph.D., associate professor at the University of California, Berkeley, followed by an engaging Q&A session.
- practical insights and real-world results into the impact of myopia management from Carlee Young, OD, FAAO.
Katherine Schuetz, OD, then facilitated a panel that featured interviews with both parents and children, offering authentic feedback on how MiSight® 1 day has positively influenced their daily lives and shaped their future vision health.
The event was designed around an elementary school theme, which tied into the “CooperVision Elementary” booth on the Academy show floor. This playful yet purposeful concept highlighted the necessity of early intervention in childhood myopia, reinforcing the idea that timely action is crucial for effective management and long-term eye health in young patients.2
For more information, visit MiSight.com.
###
Footnotes:
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† ActivControl® technology in MiSight® 1 day contact lenses slows axial length elongation and corrects refractive error for age-appropriate children.
‡ MiSight® 1 day shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.
¶ Compared to a single vision 1 day lens over a 3 year period.
References:
1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
2. Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week, and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, visit www.coopercos.com
Media Contact
Laura DiCaprio, Senior Counselor
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-434-2153